Stock MDR MEDADVISOR LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings MedAdvisor Limited

Equities

MDR

AU000000MDR6

Market Closed - Australian S.E.
Other stock markets
 02:10:13 2024-05-03 am EDT 		5-day change 1st Jan Change
0.31 AUD +1.64% Intraday chart for MedAdvisor Limited +5.08% +44.19%
Apr. 24 MedAdvisor Operating Revenue Rises 42% to AU$24.2 Million in March Quarter MT
Apr. 23 MedAdvisor's Gross Profit Climbs 48.5% in Fiscal Q3, Revenue Rises 42.4% MT

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 53% by 2026.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • The company is highly valued given the cash flows generated by its activity.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

1st Jan change Capi. Investor Rating ESG Refinitiv
MEDADVISOR LIMITED Stock MedAdvisor Limited
+44.19% 113M -
VEEVA SYSTEMS INC. Stock Veeva Systems Inc.
+5.70% 32.88B
C
PRO MEDICUS LIMITED Stock Pro Medicus Limited
+18.46% 7.84B
C-
SECTRA AB Stock Sectra AB
+22.71% 3.95B
B-
EVOLENT HEALTH, INC. Stock Evolent Health, Inc.
-17.95% 3.11B
C-
OMNICELL, INC. Stock Omnicell, Inc.
-19.93% 1.38B
B
LUNIT INC. Stock Lunit Inc.
-30.65% 1.21B -
SIMULATIONS PLUS, INC. Stock Simulations Plus, Inc.
+4.36% 933M
C
B-SOFT CO.,LTD. Stock B-SOFT Co.,Ltd.
-34.81% 911M -
VERADIGM INC. Stock Veradigm Inc.
-26.60% 829M -
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. MDR Stock
  4. Ratings MedAdvisor Limited